Physician profile
Ying Vang
NPI 1861804569
$2,354.86
in general payments reported to CMS, 2019-2025
29 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $272 · 2021: $538 · 2022: $517 · 2023: $295 · 2024: $293 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $555.62 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $304.56 | 2019-2025 | |
| Abbvie INC. | $160.89 | 2022-2025 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.33 | 2020-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $122.94 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $118.02 | 2019-2022 | |
| Amgen INC. | $107.06 | 2019-2024 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $105.63 | 2019-2025 | Breztri |
| Abbott Laboratories | $93.76 | 2021-2022 | |
| Glaxosmithkline, LLC. | $71.52 | 2019-2024 | Arexvy, Shingrix |
| Dexcom, INC. | $67.95 | 2021-2022 | |
| Amarin Pharma, INC. | $62.20 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $56.29 | 2020-2022 | |
| Eisai INC. | $48.07 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $43.76 | 2021-2024 | Jynarque |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $33.65 | 2023-2024 | |
| Lilly USA, LLC | $33.63 | 2022-2023 | Mounjaro |
| Kaleo, INC. | $33.48 | 2020-2021 | |
| Bausch Health US, LLC | $29.78 | 2019-2022 | |
| Baxter Healthcare | $24.59 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $20.62 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.10 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.65 | 2020 | |
| Corium, LLC | $14.40 | 2022 | |
| Astellas Pharma US INC | $13.86 | 2024 | Veozah |
| Boston Scientific Corporation | $13.84 | 2022 | |
| Inari Medical, INC. | $13.34 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $12.68 | 2022 | |
| Sanofi Pasteur INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ying Vang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.